高度质瘤的多变量回顾分析:生存和预后因素
Weiyan Shi1,2,3, Xuanzhong Wang1,2,3, Shiyu Liu1,2,3
1Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, China.
Cancer medicine
|August 9, 2024
概括
高度质瘤 (HGGs) 的存活率受到瘤等级和并发化学放射治疗的显著影响. MGMT表达也影响无进展生存 (PFS),较高的TRIB3和AURKA表达与较差的结果有关.
科学领域:
- 神经瘤学神经瘤学
- 癌症研究 癌症研究
- 临床瘤学临床瘤学
背景情况:
- 高度质瘤 (HGGs) 是具有不良预后的侵袭性脑瘤.
- 了解生存结果和预后因素对于改善患者管理至关重要.
研究的目的:
- 调查HGGs患者的生存结果.
- 确定影响整体生存 (OS) 和无进展生存 (PFS) 的预后因素.
主要方法:
- 对159名组织学证实HGGs的患者进行了回顾性分析.
- 卡普兰-梅尔生存分析和考克斯回归被用来评估生存数据.
- 进行免疫组织化学检查以评估预后标志物.
主要成果:
- 一年,两年和五年的OS率分别为81.8%,50.3%和12.6%;中位数的OS为35个月.
- 瘤等级,年龄,病理分类,ki-67,MGMT和IDH1R132H表达与PFS有关.
- 增加的TRIB3和AURKA表达与较短的存活时间相关.
结论:
- 瘤等级和并发化学放射治疗是OS的独立预后因素.
- 瘤等级和MGMT表达是PFS的独立预后因素.
- TRIB3和AURKA表达水平表明生存结果较差.
相关概念视频
Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
Comparing the Survival Analysis of Two or More Groups
166
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
166
Kaplan-Meier Approach
115
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
115


